




RealRate

PHARMACEUTICAL 2019

International Stem Cell CORP
Rank 145 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of International Stem Cell CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 629% points. The greatest weakness of International Stem Cell CORP is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 200% points.

The company's Economic Capital Ratio, given in the ranking table, is -90%, being 242% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	3,770
Cost of Goods Sold	4,069
Intangible Assets	2,674
Liabilities, Current	5,077
Liabilities, Non-Current	0
Other Assets	883
Other Compr. Net Income	0
Other Expenses	2,631
Other Liabilities	182
Other Net Income	1,343
Property and Equipment	469
Research and Development	2,396
Revenues	11,089
Selling, General and Administrative Expense	5,467

Output Variable	Value in 1000 USD
Assets	7,796
Liabilities	5,259
Expenses	14,563
Stockholders Equity	2,537
Net Income	-2,131
Comprehensive Net Income	-2,131
Economic Capital Ratio	-90%